
Fate Therapeutics, Inc.: updates and filings
Price
$0.92
November 20, 2026Market cap $107M
What Ploutos Investor adds for Fate Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 50% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.85 then, $0.92 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026FilingFormEFFECT
- Nov 9, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 5, 2026Shelf registration for future offeringsFormS-3
- Nov 5, 2026Material agreement entered, material agreement endedForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Sep 28, 2026Other material eventsForm8-K
- Aug 13, 2026Shares registered for employeesFormS-8
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 15, 2026Officer or director change, shareholder voteForm8-K
- Jun 4, 2026Other material eventsForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Additional annual meeting materialFormDEFA14A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 22, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Nov 13, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 13, 2025Results of operationsForm8-K
- Oct 27, 2025Regulation FD disclosure, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | EFFECT | Filing | Document |
| Nov 9, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 5, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 5, 2026 | 8-K | Material agreement entered, material agreement ended | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Sep 28, 2026 | 8-K | Other material events | Document |
| Aug 13, 2026 | S-8 | Shares registered for employees | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 15, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 4, 2026 | 8-K | Other material events | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 22, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Nov 13, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 13, 2025 | 8-K | Results of operations | Document |
| Oct 27, 2025 | 8-K | Regulation FD disclosure, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 2, 2008.
The full analysis
What do Fate Therapeutics's filings show?
The filings are where every one of Fate Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.